This article was originally published in The Gray Sheet
Boston Scientific launches a 630-patient clinical trial to evaluate the value of target aneurysm recurrence as an endpoint for trials of endovascular devices to treat brain aneurysms. The Matrix and Platinum Science (MAPS) trial randomizes patients with brain aneurysms to be treated with either Boston Scientific's GDC detachable coil or its Matrix2 detachable coil. The primary endpoint of the 50-center trial is target aneurysm recurrence, defined as a composite of target aneurysm reintervention, target aneurysm rupture or rerupture, and death...
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.